Dublin, Dec. 10, 2015 (GLOBE NEWSWIRE) -- Research and Markets ( http://www.researchandmarkets.com/research/sq..._precision ) has announced the addition of the "Global Precision Medicine Market - Estimates and Forecasts Through (2015-2022)" report to their offering. Recently, in a speech at the White House, American President Obama unveiled his Precision Medicine Initiative, a two-hundred-and-fifteen-million-dollar plan to collect genetic information from a million American volunteers in order to further the development of personalized, genetics-based medical treatments. Obama called precision medicine one of the greatest opportunities for new medical breakthroughs that we have ever seen. Following this, the major French drug company Sanofi has recently announced that their Praluent drug can significantly reduce low-density lipoprotein cholesterol (LDL-C), which is often called bad cholesterol. The company further revealed that Praluent has received a green signal from the European Commission for treating adult patients suffering from hypercholesterolemia and LDL cholesterol. Most of the advancements in this market are being driven by advancements in precision oncology techniques. As a result a patient diagnosed with cancer in 2004 would have had only a 10% chance of obtaining the right treatment for the disease as compared to a 70-80% chance of getting the right treatment today. With these crucial segments setting pace, the global precision market is set to be valued at close to $88 billion by 2022 at an estimated CAGR of 12.60% from 2015 to 2022 with North America and Europe setting pace for the Rest of the World, according to Global Precision Medicine Market - Estimation & Forecast (2015-2022) report. The growth in the precision medicine market is propelled by an increasing demand for personalized treatment, technological innovation and advancement (including Biomarker-based tests/kits, next gene sequencing, and precise imaging), Government support and regulations. The main aim of these regulations is to make precision medicines more adaptable and focused towards genetic diseases related to Oncology, skin, respiratory, CNS, CVD, and infectious diseases among others. The patients are benefitted indirectly by these regulations as it save time and cut-down cost as the patients get the required treatment for the specific disease. The report presents a thorough analysis of the entire precision medicine ecosystem and provides extensive insights of the different developments, trends and key participants. It also focuses on different sub-markets which help in the development of precision medicine solutions. While highlighting the principal driving and restraining forces for this dynamic market, the report also provides a comprehensive section of the prominent consortiums, compliance, and regulatory bodies and their involvement in the precision medicine market. The report includes the profiles of major players in the precision medicine market that allows its readers to get an insight into the industry trends. Key Topics Covered: 1 Report Scope 2 Executive Summary 3 Market Overview 4 Market Dynamics 5 Industry Dynamics 6 Global Precision Medicine Market By Ecosystem Players 7 Global Precision Medicine Market By Sub-Markets 9 Global Precision Medicine Market By Geography 10 Company Profiles - AB-Biotics Sa - Abbott Laboratories - Almac Group, Ltd. - Asuragen, Inc. - Biobase Gmbh (Subsidiary) - Biomérieux Sa - Caris Life Sciences - Cepheid Inc. - Cetics Healthcare Technologies Gmbh - GE Healthcare - Glaxosmithkline Plc (Gsk) - Healthcore, Inc. - IBM - Intel Corporation - Intomics A/S - Johnson & Johnson - Laboratory Corporation Of America Holdings - Medtronic - Novartis - Qiagen - Quest Diagnostics Inc - Randox Laboratories Ltd. - Roche Holding Ag-Br - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries Ltd. For more information visit http://www.researchandmarkets.com/research/sq..._precision
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Sector: Pharmaceuticals
